Evidence map›Paper›PMID 34395368›Full record

ArticleFrontiers in public health2021

A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19.

Emmanuelle Logette, Charlotte Lorin, Cyrille Favreau, Eugenia Oshurko, Jay S Coggan, Francesco Casalegno, Mohameth François Sy, Caitlin Monney, Marine Bertschy, Emilie Delattre and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Potential ofBioMed research international · 2022
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Emmanuelle LogetteBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Charlotte LorinBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Cyrille FavreauBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Eugenia OshurkoBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Jay S CogganBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Francesco CasalegnoBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Mohameth François SyBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Caitlin MonneyBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Marine BertschyBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Emilie DelattreBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Pierre-Alexandre FontaBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Jan KreplBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Stanislav SchmidtBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Daniel KellerBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Samuel KerrienBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Enrico ScantamburloBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Anna-Kristin KaufmannBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
Henry MarkramBlue Brain Project, École polytechnique fédérale de Lausanne (EPFL), Geneva, Switzerland.
École Polytechnique Fédérale de Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 started spreading toward the end of 2019 causing COVID-19, a disease that reached pandemic proportions among the human population within months. The reasons for the spectrum of differences in the severity of the disease across the population, and in particular why the disease affects more severely the aging population and those with specific preconditions are unclear. We developed machine learning models to mine 240,000 scientific articles openly accessible in the CORD-19 database, and constructed knowledge graphs to synthesize the extracted information and navigate the collective knowledge in an attempt to search for a potential common underlying reason for disease severity. The machine-driven framework we developed repeatedly pointed to elevated blood glucose as a key facilitator in the progression of COVID-19. Indeed, when we systematically retraced the steps of the SARS-CoV-2 infection, we found evidence linking elevated glucose to each major step of the life-cycle of the virus, progression of the disease, and presentation of symptoms. Specifically, elevations of glucose provide ideal conditions for the virus to evade and weaken the first level of the immune defense system in the lungs, gain access to deep alveolar cells, bind to the ACE2 receptor and enter the pulmonary cells, accelerate replication of the virus within cells increasing cell death and inducing an pulmonary inflammatory response, which overwhelms an already weakened innate immune system to trigger an avalanche of systemic infections, inflammation and cell damage, a cytokine storm and thrombotic events. We tested the feasibility of the hypothesis by manually reviewing the literature referenced by the machine-generated synthesis, reconstructing atomistically the virus at the surface of the pulmonary airways, and performing quantitative computational modeling of the effects of glucose levels on the infection process. We conclude that elevation in glucose levels can facilitate the progression of the disease through multiple mechanisms and can explain much of the differences in disease severity seen across the population. The study provides diagnostic considerations, new areas of research and potential treatments, and cautions on treatment strategies and critical care conditions that induce elevations in blood glucose levels.

Indexed as

COVID-19AgedBlood GlucoseCytokine Release SyndromeHumansInflammationSARS-CoV-2Blood GlucosecarbohydratesCOVID-19glucoseglycolysisglycosylationhyperglycemiaketogenic dietSARS-CoV-2

Identifiers

PMID34395368
PMCPMC8356061
OpenAlexW3185291249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.